HC Wainwright Reiterates “Buy” Rating for Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 412.82% from the stock’s current price.

Entera Bio Stock Performance

ENTX stock opened at $1.95 on Tuesday. The company has a fifty day moving average price of $2.20 and a 200-day moving average price of $2.02. The company has a market capitalization of $69.78 million, a P/E ratio of -7.50 and a beta of 1.62. Entera Bio has a 52-week low of $1.30 and a 52-week high of $3.35.

Hedge Funds Weigh In On Entera Bio

Large investors have recently modified their holdings of the business. Perigon Wealth Management LLC bought a new position in shares of Entera Bio during the fourth quarter valued at $325,000. Northern Trust Corp bought a new position in Entera Bio during the fourth quarter worth $450,000. Parkman Healthcare Partners LLC raised its stake in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after buying an additional 9,558 shares during the last quarter. Finally, Knoll Capital Management LLC raised its stake in Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after buying an additional 2,000,000 shares during the last quarter. Institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.